Bioblast Announces Effectiveness of Eight to One Reverse Split
06 mars 2019 06h00 HE
|
Bioblast Pharma Ltd.
Tel Aviv, Israel, March 06, 2019 (GLOBE NEWSWIRE) -- Bioblast Pharma Ltd. (NasdaqCM: ORPN), a clinical-stage, orphan disease-focused biotechnology company, announced the effectiveness of an eight to...
Bioblast Pharma Announces Sale of its Trehalose Clinical Development Programs to Seelos Therapeutics
19 févr. 2019 07h45 HE
|
Bioblast Pharma Ltd.
Unconditional payment of $3.5 million Contingent payment of up to additional $17 million plus royaltiesSeelos to receive rights also to the Trehalose for Sanfilippo Syndrome Program Tel Aviv,...
Bioblast Pharma Announces Collaboration with Team Sanfilippo to Evaluate Trehalose for the Treatment of Sanfilippo Syndrome
14 févr. 2019 19h05 HE
|
Bioblast Pharma Ltd.
Tel Aviv, Israel, Feb. 14, 2019 (GLOBE NEWSWIRE) -- Bioblast Pharma Ltd. (NasdaqCM: ORPN) (“Bioblast”), a clinical-stage, orphan disease-focused biotechnology company, and Team Sanfilippo (“TSF”), a...
Bioblast Pharma Ltd. Announces Receipt of Nasdaq Notification Regarding Minimum Stockholders’ Equity Non-Compliance
11 janv. 2019 16h05 HE
|
Bioblast Pharma Ltd.
Tel Aviv, Israel, Jan. 11, 2019 (GLOBE NEWSWIRE) -- Bioblast Pharma Ltd. (NasdaqCM: ORPN) (“Bioblast” or the “Company”), a clinical-stage, orphan disease-focused biotechnology company, announced...
Bioblast Pharma Ltd. Announces Entry Into Merger Agreement to Acquire Enlivex Therapeutics Ltd. to Advance Clinical Stage Immunotherapeutic Drug Pipeline for the Treatment of Life-Threatening Diseases Sepsis, GvHD and Solid Tumors
19 nov. 2018 16h15 HE
|
Bioblast Pharma Ltd.
Enlivex Therapeutics is a private, venture-funded clinical stage immunotherapy company developing an allogeneic drug pipeline for immune system rebalancing, which is critical for the treatment of...
Bioblast Pharma Ltd. Corporate and Management Update
26 juil. 2018 16h15 HE
|
Bioblast Pharma Ltd.
TEL AVIV, Israel and NEW YORK, July 26, 2018 (GLOBE NEWSWIRE) -- Bioblast Pharma Ltd. (Nasdaq:ORPN) is providing an update on business development activities as well as notice of an organization...
Bioblast Pharma Reports Third Quarter 2017 Financial Results
02 nov. 2017 07h30 HE
|
Bioblast Pharma Ltd.
TEL AVIV, Israel, Nov. 02, 2017 (GLOBE NEWSWIRE) -- Bioblast Pharma Ltd. (Nasdaq:ORPN), a clinical-stage, orphan disease-focused biotechnology company, today announced financial results for the...
Bioblast Announces Effectiveness of Five to One Reverse Split
25 sept. 2017 07h00 HE
|
Bioblast Pharma
Ordinary Shares Will Begin Trading on a Split-Adjusted Basis on September 25, 2017 TEL AVIV, Israel, Sept. 25, 2017 (GLOBE NEWSWIRE) -- Bioblast Pharma Ltd. (NasdaqCM:ORPN), a clinical-stage,...
Bioblast Pharma Reports Second Quarter 2017 Financial Results
04 août 2017 16h15 HE
|
Bioblast Pharma
TEL AVIV, Israel, Aug. 04, 2017 (GLOBE NEWSWIRE) -- Bioblast Pharma Ltd. (Nasdaq:ORPN), a clinical-stage, orphan disease-focused biotechnology company, today announced financial results for the...
Bioblast Pharma to Seek Strategic Alternatives Including Partnership and Merger Opportunities
05 juin 2017 16h15 HE
|
Bioblast Pharma
JSB-Partners Engaged to Lead the Effort Company Receives Regulatory Clearance to Initiate a Phase 2b trial of Trehalose in OPMD patients TEL AVIV, Israel, June 05, 2017 (GLOBE NEWSWIRE) --...